For any queries, please contact Customer Services or your Account Manager. Dismiss
Antitrust - Intellectual Property - Lupin - Astellas - Litigation over Myrbetriq extended-release tablets (US)
Astellas Pharma filed a US patent complaint against Lupin, Sandoz, and other companies over Myrbetriq extended-release tablets. Lupin and Zydus Pharmaceuticals filed counterclaims in Astellas' patent case, accusing it of maintaining a monopoly over the market for the active ingredient of Myrbetriq by manipulating the patent process to strategically time the issuance of duplicative patents and by repeatedly filing successive and duplicative patent infringement actions based on patents covering the same or similar subject matter, which actions and patents are designed to interfere with generic manufacturers entering into the market.
Timeline
Parties
Get the inside track, with MLex
With a global network of expert journalists digging deep into the areas of risk that matter to your business and clients—and the highest standards of impartiality—you can have complete trust in MLex to keep you ahead of the regulatory curve.
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from specialists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
TRY MLEX FREE FOR 14 DAYS
Already a subscriber? Click here to login